Amrutanjan Health Care Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹118Cr
- +7.3% YoY
- +25.5% QoQ
- Net profit
- ₹14Cr
- +16.7% YoY
- +75% QoQ
- Margin
- 14%
- +2 pp YoY
- +5 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Amrutanjan Health Care Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY26 Revenue from Operations: Rs. 117.70 Cr, up 7.08% YoY (Page 22). Q2 FY26 EBITDA: Rs. 24.42 Crores, up 19.95% YoY (from Rs. 20.35 Crores in Q2 FY25) [Page 31].
From Amrutanjan Health Care Ltd's Q2 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q2 FY26 Revenue from Operations: Rs. 117.70 Cr, up 7.08% YoY (Page 22)
- Q2 FY26 Gross Sales: Rs. 132.49 Cr, up 9.76% YoY (Page 22)
- Q2 FY26 Net Sales - OTC: Rs. 112.80 Cr, up 6.15% YoY (Page 23)
- Q2 FY26 Net Sales – Comfy: Rs. 32.78 Cr, slight decline vs Rs. 33.00 Cr YoY (Page 23)
- Q2 FY26 Gross Sales - Beverages: Rs. 5.25 Cr, up 33.93% YoY (Page 24)
- H1 FY26 Revenue from Operations: Rs. 211.75 Cr, up 9.35% YoY (Page 25)
- H1 FY26 Gross Sales: Rs. 239.68 Cr, up 11.86% YoY (Page 25)
- H1 FY26 Net Sales - OTC: Rs. 198.38 Cr, up 10.89% YoY (Page 26)
- H1 FY26 Net Sales – Comfy: Rs. 61.39 Cr, up 3.04% YoY (Page 26)
- Management commentary notes softer Q2 topline due to new GST law effective late September (Page 30)
2 more points from Amrutanjan Health Care Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Amrutanjan Health Care Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Sanitary napkin plant:
- - Will be commissioned by late Q4 FY26
- - Expected to be a strong enabler of Comfy brand profitability and strategic supply
- SAP Implementation for Comfy Plant:
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Amrutanjan Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Amrutanjan Health Care Ltd said on order book & pipeline — free account, 30 seconds.
Amrutanjan Health Care Ltd — Quarterly revenue & net profit
Amrutanjan Health Care Ltd Q2 FY26 results — key figures
| ₹ Cr | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 118 | 110 | +7.3% | 94 | +25.5% |
| Operating profit (EBITDA) | 17 | 14 | +21.4% | 8 | +112.5% |
| Operating margin | 14% | 12% | +2 pp | 9% | +5 pp |
| Profit before tax | 19 | 16 | +18.8% | 11 | +72.7% |
| Net profit (PAT) | 14 | 12 | +16.7% | 8 | +75% |
| EPS (₹) | 4.83 | 4.08 | +18.4% | 2.87 | +68.3% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹135 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Amrutanjan Healt's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q2 FY25 earnings call analysis →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call analysis →
Earlier calls (1)
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Amrutanjan Health Care Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Amrutanjan Health Care Ltd Q2 FY26 results?
Q2 FY26 Revenue from Operations: Rs. 117.70 Cr, up 7.08% YoY (Page 22). Q2 FY26 EBITDA: Rs. 24.42 Crores, up 19.95% YoY (from Rs. 20.35 Crores in Q2 FY25) [Page 31].
What is Amrutanjan Health Care Ltd share price analysis?
Amrutanjan Health Care Ltd currently shows a neutral. The stock trades at a P/E of 22.9 with a market cap of ₹1,428 Cr. Investors should review the full earnings analysis for detailed insights.
Is Amrutanjan Health Care Ltd planning capital expenditure?
Sanitary napkin plant: - Will be commissioned by late Q4 FY26 - Expected to be a strong enabler of Comfy brand profitability and strategic supply - SAP Implementation for Comfy Plant: - In progr
Keep Amrutanjan Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
